Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.

Bruno A, Schirosi M, Foti R

Aesthetic plastic surgery7 Apr 2026

PMID41944875DOI10.1007/s00266-026-05805-3PepBankPUB-41944875

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative CRP rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, CRP rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreasePostoperative CRP rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Inflammation markers · Immune and inflammation
Measurements
CRP increase
18 mg/L
GLP-1 RA
CRP increase
28 mg/L
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487501
02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative CRP rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, CRP rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreasePostoperative CRP rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Inflammation markers · Immune and inflammation
Measurements
CRP increase
18 mg/L
GLP-1 RA
CRP increase
28 mg/L
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487502
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative IL-6 rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, IL-6 rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreasePostoperative IL-6 rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Inflammation markers · Immune and inflammation
Measurements
IL-6 increase
12 pg/mL
GLP-1 RA
IL-6 increase
20 pg/mL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487503
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative IL-6 rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, IL-6 rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreasePostoperative IL-6 rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Inflammation markers · Immune and inflammation
Measurements
IL-6 increase
12 pg/mL
GLP-1 RA
IL-6 increase
20 pg/mL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487504
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative fibrinogen rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, fibrinogen rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreasePostoperative fibrinogen rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Fibrinogen increase
40 mg/dL
GLP-1 RA
Fibrinogen increase
65 mg/dL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487505
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative fibrinogen rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, fibrinogen rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreasePostoperative fibrinogen rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Fibrinogen increase
40 mg/dL
GLP-1 RA
Fibrinogen increase
65 mg/dL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487506
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative D-dimer rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, D-dimer rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreasePostoperative D-dimer rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
D-dimer increase
0.8 µg/mL
GLP-1 RA
D-dimer increase
1.3 µg/mL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487507
08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative D-dimer rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, D-dimer rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreasePostoperative D-dimer rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
D-dimer increase
0.8 µg/mL
GLP-1 RA
D-dimer increase
1.3 µg/mL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487508
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative PAI-1 rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, PAI-1 rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreasePostoperative PAI-1 rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
PAI-1 increase
5 ng/mL
GLP-1 RA
PAI-1 increase
9 ng/mL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487509
10HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) attenuated the postoperative PAI-1 rise versus lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, PAI-1 rose less with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreasePostoperative PAI-1 rise
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
PAI-1 increase
5 ng/mL
GLP-1 RA
PAI-1 increase
9 ng/mL
lifestyle
Source sentences
Summary
Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487510
11HumanNot a test of Semaglutide aloneObservational studySafety outcome
In women undergoing abdominoplasty, no symptomatic VTE occurred with pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide), versus two cases (6.7%) with lifestyle-induced weight loss; no test was reported.
In plain wordsAfter abdominoplasty, no symptomatic blood clots occurred with GLP-1 drugs (semaglutide or tirzepatide, pooled) versus two with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreaseSymptomatic VTE
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Symptomatic VTE incidence
6.7%
lifestyle controls
Source sentences
Summary
No symptomatic VTE occurred in the GLP-1 group versus two cases (6.7%) in controls
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487511
12HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In women undergoing abdominoplasty, no symptomatic VTE occurred with pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide), versus two cases (6.7%) with lifestyle-induced weight loss; no test was reported.
In plain wordsAfter abdominoplasty, no symptomatic blood clots occurred with GLP-1 drugs (semaglutide or tirzepatide, pooled) versus two with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreaseSymptomatic VTE
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Symptomatic VTE incidence
6.7%
lifestyle controls
Source sentences
Summary
No symptomatic VTE occurred in the GLP-1 group versus two cases (6.7%) in controls
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487512
13HumanNot a test of Semaglutide aloneObservational studySafety outcome
In women undergoing abdominoplasty, subclinical DVT occurred in 3.3% with pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) versus 10% with lifestyle-induced weight loss; no test was reported.
In plain wordsAfter abdominoplasty, symptom-free blood clots were less frequent with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreaseSubclinical DVT
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Subclinical DVT incidence
3.3%
GLP-1 RA
Subclinical DVT incidence
10%
lifestyle controls
Source sentences
Summary
subclinical DVT occurred in 1 (3.3%) versus 3 (10%)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487513
14HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In women undergoing abdominoplasty, subclinical DVT occurred in 3.3% with pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) versus 10% with lifestyle-induced weight loss; no test was reported.
In plain wordsAfter abdominoplasty, symptom-free blood clots were less frequent with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreaseSubclinical DVT
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Bleeding and clotting · Cardiovascular
Measurements
Subclinical DVT incidence
3.3%
GLP-1 RA
Subclinical DVT incidence
10%
lifestyle controls
Source sentences
Summary
subclinical DVT occurred in 1 (3.3%) versus 3 (10%)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487514
15HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, hospital stay was shorter with pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) than with lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, hospital stay was shorter with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Semaglutide
Outcome
DecreaseHospital stay
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Intensive care and hospital outcomes · Whole body
Measurements
Hospital stay
1.8 days
GLP-1 RA
Hospital stay
2.2 days
lifestyle
Source sentences
Summary
Hospital stay was shorter with GLP-1 therapy (1.8 vs. 2.2 days, p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194487515
16HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In women undergoing abdominoplasty, hospital stay was shorter with pooled preoperative GLP-1 receptor agonists (semaglutide or tirzepatide) than with lifestyle-induced weight loss.
In plain wordsAfter abdominoplasty, hospital stay was shorter with GLP-1 drugs (semaglutide or tirzepatide, pooled) than with lifestyle weight loss.
Peptide
Tirzepatide
Outcome
DecreaseHospital stay
Study
n = 60
Comparator
Lifestyle-induced weight loss
Outcome group
Intensive care and hospital outcomes · Whole body
Measurements
Hospital stay
1.8 days
GLP-1 RA
Hospital stay
2.2 days
lifestyle
Source sentences
Summary
Hospital stay was shorter with GLP-1 therapy (1.8 vs. 2.2 days, p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m² before weight loss) undergoing standardized abdominoplasty with rectus plication.
Summary · context
Two cohorts were compared: (1) 30 patients treated with GLP-1 RAs (semaglutide or tirzepatide) for ≥12 weeks preoperatively, and (2) 30 patients achieving comparable weight loss through structured lifestyle intervention.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4194487516

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.